Polygonumins A, a newly isolated compound from the stem of Polygonum minus Huds with potential medicinal activities
Polygonumins A, a new compound, was isolated from the stem of Polygonum minus. Based on NMR results, the compound's structure is identical to that of vanicoside A, comprising four phenylpropanoid ester units and a sucrose unit. The structure differences were located at C-3″″'. The cytotoxic activity of polygonumins A was evaluated on several cancer cell lines by a cell viability assay using tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). The compound showed the highest antiproliferative (p < 0.05) activities against K562 (Human Leukaemia Cell Line), MCF7 (Human breast adenocarcinoma cell line), and HCT116 (Colorectal cancer cells) cells. Cytotoxic studies against V79-4 cells were carried out and showed that polygonumins A was toxic at 50 µg/ml, suggesting that this compound may be used as an anticancer drug without affecting normal cells. Polygonumins A also showed promising activity as an HIV-1 protease inhibitor with 56% relative inhibition. Molecular docking results indicated that the compound possesses high binding affinity towards the HIV protease over the low binding free energy range of -10.5 to -11.3 kcal/mol. P. minus is used in Malaysian traditional medicine for the treatment of tumour cells. This is the first report on the use of P. minus as an HIV-1 protease inhibitor.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Scientific reports - 8(2018), 1 vom: 09. März, Seite 4202 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ahmad, Rafidah [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.09.2019 Date Revised 27.09.2019 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-018-22485-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM281803455 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM281803455 | ||
| 003 | DE-627 | ||
| 005 | 20231226194850.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-018-22485-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0939.xml |
| 035 | |a (DE-627)NLM281803455 | ||
| 035 | |a (NLM)29523802 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ahmad, Rafidah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Polygonumins A, a newly isolated compound from the stem of Polygonum minus Huds with potential medicinal activities |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.09.2019 | ||
| 500 | |a Date Revised 27.09.2019 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Polygonumins A, a new compound, was isolated from the stem of Polygonum minus. Based on NMR results, the compound's structure is identical to that of vanicoside A, comprising four phenylpropanoid ester units and a sucrose unit. The structure differences were located at C-3″″'. The cytotoxic activity of polygonumins A was evaluated on several cancer cell lines by a cell viability assay using tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). The compound showed the highest antiproliferative (p < 0.05) activities against K562 (Human Leukaemia Cell Line), MCF7 (Human breast adenocarcinoma cell line), and HCT116 (Colorectal cancer cells) cells. Cytotoxic studies against V79-4 cells were carried out and showed that polygonumins A was toxic at 50 µg/ml, suggesting that this compound may be used as an anticancer drug without affecting normal cells. Polygonumins A also showed promising activity as an HIV-1 protease inhibitor with 56% relative inhibition. Molecular docking results indicated that the compound possesses high binding affinity towards the HIV protease over the low binding free energy range of -10.5 to -11.3 kcal/mol. P. minus is used in Malaysian traditional medicine for the treatment of tumour cells. This is the first report on the use of P. minus as an HIV-1 protease inhibitor | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antineoplastic Agents, Phytogenic |2 NLM | |
| 650 | 7 | |a Cinnamates |2 NLM | |
| 650 | 7 | |a HIV Protease Inhibitors |2 NLM | |
| 650 | 7 | |a vanicoside A |2 NLM | |
| 650 | 7 | |a 155179-22-9 |2 NLM | |
| 650 | 7 | |a HIV Protease |2 NLM | |
| 650 | 7 | |a EC 3.4.23.- |2 NLM | |
| 650 | 7 | |a p16 protease, Human immunodeficiency virus 1 |2 NLM | |
| 650 | 7 | |a EC 3.4.23.- |2 NLM | |
| 700 | 1 | |a Sahidin, I |e verfasserin |4 aut | |
| 700 | 1 | |a Taher, Muhammad |e verfasserin |4 aut | |
| 700 | 1 | |a Low, ChenFei |e verfasserin |4 aut | |
| 700 | 1 | |a Noor, Normah Mohd |e verfasserin |4 aut | |
| 700 | 1 | |a Sillapachaiyaporn, Chanin |e verfasserin |4 aut | |
| 700 | 1 | |a Chuchawankul, Siriporn |e verfasserin |4 aut | |
| 700 | 1 | |a Sarachana, Tewarit |e verfasserin |4 aut | |
| 700 | 1 | |a Tencomnao, Tewin |e verfasserin |4 aut | |
| 700 | 1 | |a Iskandar, Faizah |e verfasserin |4 aut | |
| 700 | 1 | |a Rajab, Nor Fadilah |e verfasserin |4 aut | |
| 700 | 1 | |a Baharum, Syarul Nataqain |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 8(2018), 1 vom: 09. März, Seite 4202 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2018 |g number:1 |g day:09 |g month:03 |g pages:4202 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-018-22485-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2018 |e 1 |b 09 |c 03 |h 4202 | ||